Pathogenic autoantibodies and diverse antigens

Pathogenic autoantibodies and diverse antigens represent a broad category of immune components central to the development and progression of autoimmune diseases. Autoantibodies are specialized immunoglobulins produced by B cells that mistakenly identify and attack the body's own tissues, while the "diverse antigens" refer to the wide array of self-molecules—including proteins, nucleic acids, and lipids—that these antibodies target (StatPearls, 2023). This misdirected immune response leads to chronic inflammation, tissue damage, and systemic or organ-specific dysfunction, characterizing conditions such as systemic lupus erythematosus, rheumatoid arthritis, and myasthenia gravis (National Institutes of Health, 2023). Because this entry describes a broad pathological state rather than a single molecular target, therapeutic intervention typically focuses on general mechanisms such as depleting B-cell lineages, inhibiting the neonatal Fc receptor (FcRn) to accelerate the clearance of pathogenic IgG, or using plasmapheresis to physically remove antibodies from circulation (Ludwig et al., 2017, Frontiers in Immunology). Understanding the specific interactions between these antibodies and their cognate antigens is essential for the development of targeted diagnostics and precision therapies in rheumatology, neurology, and dermatology.

Other names

AutoantibodiesSelf-antigensAutoantigensPathogenic immunoglobulinsAutoimmune targets

Therapeutic strategies involve reducing the concentration of pathogenic autoantibodies through B-cell depletion (e.g., via CD20 targeting), blocking the neonatal Fc receptor (FcRn) to prevent IgG recycling and promote degradation, or neutralizing the antibodies using intravenous immunoglobulin (IVIG) (Ludwig et al., 2017, Frontiers in Immunology; Gable et al., 2020, Nature Reviews Rheumatology).